Navidea Biopharmaceuticals (NAVB)s’ NAV4694 ß-Amyloid Imaging Agent to Be Used in Alzheimer’s Disease Studies by Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL)
7/16/2013 10:09:44 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) plans to switch to using Navidea’s Fluorine-18 labeled ß-amyloid imaging candidate, NAV4694, from 11C-labeled Pittsburgh Compound-B (PiB) for its comprehensive research initiative in Alzheimer’s disease and Mild Cognitive Impairment. Dr. Christopher C. Rowe, MD FRACP, Director of the Department of Nuclear Medicine and Centre for PET at Austin Health, Melbourne, Australia, announced the changeover to NAV4694 at the World Wide Alzheimer's Disease Neuroimaging Initiative meeting in Boston, MA.
Help employers find you! Check out all the jobs and post your resume.